VEGFA and endometriosis: Bevacizumab, an anti-VEGF, non-hormonal factor has been studied for possible treatment of endometriosis; however, it carries serious, not easily tolerated side effects (i.e., gastrointestinal perforation, thrombosis, severe bleeding, impaired kidney function, and wound healing) [42].